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Abstract
Background: With time, episodes of migraine headache afflict patients with increased frequency, longer duration and
more intense pain. While episodic migraine may be defined as 1-14 attacks per month, there are no clear-cut phases
defined, and those patients with low frequency may progress to high frequency episodic migraine and the latter may
progress into chronic daily headache (> 15 attacks per month). The pathophysiology of this progression is completely
unknown. Attempting to unravel this phenomenon, we used high field (human) brain imaging to compare functional
responses, functional connectivity and brain morphology in patients whose migraine episodes did not progress (LF) to a
matched (gender, age, age of onset and type of medication) group of patients whose migraine episodes progressed (HF).
Results: In comparison to LF patients, responses to pain in HF patients were significantly lower in the caudate,
putamen and pallidum. Paradoxically, associated with these lower responses in HF patients, gray matter volume of
the right and left caudate nuclei were significantly larger than in the LF patients. Functional connectivity analysis
revealed additional differences between the two groups in regard to response to pain.
Conclusions: Supported by current understanding of basal ganglia role in pain processing, the findings suggest a
significant role of the basal ganglia in the pathophysiology of the episodic migraine.
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1. Background
Migraine is a common neurological disorder, frequently
starting in childhood and extending into adulthood. It is
defined by recurrent headaches that last 4-72 hours and
affect patients one to fourteen times each month in the
episodic form and more than fourteen attacks per month
in the chronic form. Most patients seeking medical help
are not responsive to current preventive therapies [1] that
could mitigate such progression. To identify neurological
reasons for migraine disease, we attempted to compare
brain functions and morphology in patients at the two
ends of episodic migraine spectrum: those with very low
frequency of migraine attacks vs. those with very high
frequency of migraine attacks.
Numerous imaging studies of migraine patients have
described multiple changes in brain functions as a result
of migraine attacks: these included enhanced cortical
excitability [2], increased gray matter volume in some
regions and decreased in others, [3,4]; enhanced brain
blood flow [5-7]; and altered pain modulatory systems
[8-10].
T h eB a s a lG a n g l i a( B G )a r eam a j o rs i t ef o ra d a p t i v e
plasticity in the brain, affecting in the normal state a broad
range of behaviors [11] and neurological and psychiatric
conditions [12] including pain [13,14]. The BG seem to be
involved in the integration of information between cortical
and thalamic regions and in particular the three domains
of pain processing - sensory, emotional/cognitive and
endogenous/modulatory. More recent evidence points to
BG being involved through direct connections from sen-
sory inputs (including pain (see Borsook et al., 2010) and
not involving cortical loops [15]. The BG may have a role
in that they may be involved in habit and stimulus-
response learning [16]. Such learning may be derived from
pain related regions involved in sensory (e.g., S1), affective
(e.g., cingulate or anterior insula) or cognitive regions (e.g.,
medial and lateral prefrontal cortices).
Brain imaging studies of migraineurs have shown
decreased activation in the BG of migraineurs vs. controls
[17], increased activation (blood flow) in the BG during
the ictal state and lesions in the BG of migraineurs
[18,19]. This is the first study in which attempt is made
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with those of progressing patients. In comparing the two
groups of patients such alterations may provide opportu-
nities to predict which patients progress.
2. Results
2.1. Demographics
Demographic characteristics for each cohort are noted in
Table 1. Low and high frequency migraine patients (N =
10 each, 3 male and 7 female) were matched for gender,
and age and there were no significant differences between
the age (HF: 43.2 ± 3.4 (mean ± SD), LF: 40.2 ± 3.6
(mean ± SD), (p = 0.46)) or age of onset (HF: 24.2 ± 4.4
(mean ± SD), LF: 21.6 ± 3.2 (mean ± SD), p = 0.59))
between the two cohorts. One patient in each cohort had
migraine with aura and another patient in the LF cohort
experienced auras occasionally with the migraine attacks.
The HF cohort on average had used at least 5.6 greater
triptan use during the course of their migraine disease.
There was a significant difference between the average
numbers of migraine attacks experienced in LF (1.7 ± 0.5
(mean ± SD) attacks per month) vs. HF (9.3 ± 2.6 (mean ±
SD) attacks per month) migraqineurs (p < 0.0001).
2.2. Psychophysical/Biometric Data
There were no significant differences in migraine head-
ache intensity (LF: 7.7 ± 2.4 (mean ± SD), HF: 7.2 ± 1.8
(mean ± SD), (p = 0.61)). The migraine headache unplea-
santness rating however was significantly different between
the two groups (LF: 8.5 ± 1.8 (mean ± SD), HF: 6.7 ± 1.4
(mean ± SD), (p < 0.028)), Figure 1. The average QST pain
thresholds were not significantly different (LF: 46.06 ±
4.26°C (mean ± SD), HF: 45.89 ± 2.77°C (mean ± SD), (p
= 0.83)). The average VAS scores for individually tailored
threshold + 1°C temperatures applied to the dorsum of
the hand were not significantly different for pain intensity
(LF: 8.1 ± 2.25 (mean ± SD), HF: 6.17 ± 3.4 (mean ± SD),
(p = 0.27)) or for pain unpleasantness (LF: 6.32 ± 2.58
(mean ± SD), HF: 5.47 ± 3.2 (mean ± SD), (p = 0.64)),
although there was a trend.
2.3. MRI Measures
2.3.1. Functional Analysis - Painful Heat fMRI Activation
Although data for the entire brain were acquired, strik-
ing differences was observed in basal ganglia (BG) struc-
ture and function as described below:
Contrast analysis of the HF vs. LF migraine group in
response to the “pain threshold +1°C” stimuli revealed sig-
nificant (p < 0.05, corrected) lower (HF < LF) BOLD signal
changes throughout the caudate, putamen, and pallidum
nuclei of the BG (Figure 2, and Table 2) in HF vs. LF
patients that were also symmetrical. Increased (HF > LF)
BOLD signal change (p < 0.05, corrected) was observed in
the contralateral nucleus accumbens (NAc). Single trial
averages also revealed significant reduction in the second
peak of the biphasic hemodynamic response of the caudate
(p < 0.024), putamen (p < 0.002) and pallidum (p < 0.003)
in response to noxious stimulation in the HF group relative
to the LF group.
2.3.2. Structural Analysis
High frequency migraine patients showed a larger
volume in the bilateral caudate vs. the low frequency
migraine patients (left: p < 0.025 and right: p < 0.006),
Figure 3. No other significant changes in subcortical
structures were observed.
2.3.3. Functional Connectivity (Fc) Analysis
The Fc analysis results, summarized in Figure 4 showed
significant differences between the two groups encom-
passing a number of brain regions, further suggestive of
Table 1 Demographic Data of the Studied Subjects
Group Age Age of Onset BDI Score Abortive Rx Analgesic Rx Preventive Rx
High 43.9 ± 3.37 24.2 ± 4.4 1.9 ± 2.4 80% 80% 20%
Low 40.2 ± 3.60 21.6 ± 3.2 2.1 ± 2.5 80% 50% 10%
Abortive Rx includes: Rizatriptan, Sumatriptan, and Naratriptan; Analgesic Rx includes: Iboprufen, Excedrine migraine, and Advil, and Preventive Rx includes:
Amitrityline and Verapamil.
Figure 1 Migraine Pain Intensity and Unpleasantness Ratings.
There is a significant difference in the pain unpleasantness scores
between the two cohorts (p < 0.028). The scores are based on a 0-
10 subjective scale for migraine pain intensity and pain
unpleasantness.
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Page 2 of 11Figure 2 Contrast Maps for Painful Heat fMRI Activation. Contrast analysis of the HF vs. LF migraine group in response to the “pain
threshold +1°C” stimuli revealed significant (p < 0.05, corrected) differences in the basal ganglia nuclei in coronal (A) and axial (B) views. In (C)
Single trial averages for the response to painful heat stimulation in caudate, putamen, and pallidum are presented. Yellow represents the
stimulus application period.
Table 2 Sub-cortical Clusters for Painful Heat fMRI Activation
Brain Region Lat. Max z-stat X(mm) Y(mm) Z(mm) Vol (cm
3)
HF > LF
Thalamus L 2.2586 -10 -28 8 0.352
PAG 2.1464 -6 -32 -4 1.176
Pons 2.2187 0 -26 -36 0.232
Hypothalamus L 2.8448 -10 -6 -12 1.568
HF < LF
Caudate L -1.7572 -16 20 10 1.504
Caudate R -1.7704 18 20 0 2.024
Putamen L -1.9119 -24 4 4 1.2
Putamen R -2.1153 30 2 4 1.312
Pallidium L -2.1256 -20 -2 0 0.328
Pallidium R -1.7506 16 4 -2 0.39
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two groups as described in the following:
Caudate Significantly reduced (HF < LF) Fc (p < 0.05,
corrected) of caudate was observed with ipsilateral mid-
dle frontal gyrus, ipsilateral insula, bilateral temporal
pole, and contralateral parahippocamus.
Putamen Enhanced (HF > LF) Fc (p < 0.05, corrected)
with putamen was observed in contralateral hippocam-
pus, contralateral caudate, contralateral middle frontal
gyrus and bilateral anterior insula (with a stronger con-
nectivity contralaterally).
Globus Pallidus Significantly increased (HF > LF) Fc (p <
0.05, corrected) with the pallidum was observed in bilat-
eral middle temporal gyrus, bilateral supramarginal gyrus,
bilateral thalamus, contralateral hippocampus, contralat-
eral insula, and contralateral temporal pole.
Nucleus Accumbens (NAc) Significantly reduced func-
tional connectivity with NAc was observed in bilateral
posterior cingulate cortex, ipsilateral superior parietal, and
ipsilateral hippocampus.
3. Discussion
In this multimodal imaging study, in matched groups of
HF and LF migraineurs, significant differences in gray
matter volume and function in response to pain, as mea-
sured in the interictal period, were observed in the basal
ganglia (BG). These regions are well positioned to inte-
grate sensory, motor, cognitive and other information
including behavior relating to predicting events, and in
attention and learning [20]. The BG receives inputs from
all cortical regions and the thalamus, and efferent
pathways project, mostly through BG-thalamo-cortical
loops back to the BG [20-22]. Here we report on novel
findings in the BG that were measured in HF vs. LF
migraineurs.
3.1. Basal Ganglia Functional State is Altered in HF
Migraineurs
As noted in the results, three salient observations were
noted in response to noxious heat. First, with the excep-
tion of the NAc, other BG regions showed less activation
in HF vs. LF patients. Second, bilateral activation was
observed in all regions except the NAc. Third, and perhaps
most importantly, single trial averages showed a clear loss
of the second peak of the BOLD response to pain.
The observations of decreased activation in HF vs. LF
patients in response to noxious heat have not been
reported before, although activation in the BG in
response to pain had been reported [23]. In some of the
BG regions, for example the putamen, acute pain acti-
vates the putamen somatotopically [24] an issue which
we did not resolve here based on our study design. The
relative differences between HF and LF groups observed
here is the result of the abnormal late phase BOLD
responses. A number of prior studies have shown a
biphasic response to noxious heat [25]. While the under-
lying basis for the second phase is unclear, explanations
such as differences in fiber conduction speeds (C fibers
vs. A-d fibers) would not explain the differences observed
here. Repeated activation of the somatosensory system
during migraine have not been shown to affect fiber sub-
type in the trigeminal system. An alternative explanation
might be what we had previously reported on how the
changes may reflect alterations in sensory and emotional
circuits [25]. Our current data would favor this latter
explanation, since unpleasantness ratings, but not inten-
sity ratings differed between the two groups. As noted
below, the BG are perhaps ideally located to be involved
in integration and response to a noxious stimulus. Our
prior brain imaging studies of migraine patients have
reported alterations in the BG notably the putamen, with
decreased activation in migraine patients vs. controls
[17]. The data support the notion that overall the BG
function is altered compared with healthy volunteers,
and that frequency of attacks would seem to further alter
this processing. In addition, standard MR studies of
migraine patients have reported lesions [18,19] in the
basal ganglia; potentially favoring the interpretation that
such changes are caused by the increased migraine fre-
quency rather than causing the frequency to increase. In
support of this, migraine is reportedly more frequent in
patients with known basal ganglia disorders [26]
,.
Most imaging studies of acute pain (and other aversive
events [27] report decreased activation in the nucleus
accumbens in both humans [25,28] and rats [29]. The
Figure 3 Volumetric Changes of the Caudate. The plots show the
significant caudate volumetric differences in the high vs. low
frequency migraine subjects (left: p < 0.025 and right: p < 0.006). The
volumes have been normalized to the total intracranial volume to
scale for the brain volume for each subject. Bar heights represent the
mean value for each volumetric measurement. Error bars represent
the 95% confidence interval of the mean. * denotes significance.
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increased BOLD activation (here LF > HF) may relate to
a relative emotional salience of migraine attacks over
time. The increased frequency of migraine attacks in the
H Fg r o u pi st h u sa s s o c i a t e dw i t had e c r e a s e dh e d o n i c
state [30] compared with the LF group.
3.2. Alterations in Functional Connectivity (Fc) suggest
diffuse alterations in Brain Function
I ft h eb a s a lg a n g l i ap l a ya ni m p o r t a n tr o l ei nm i g r a i n e
pathophysiology, altered functional connectivity between
different nuclei and other brain regions would be
expected. The BG project to or receive inputs from
numerous regions including the cingulate, dorsolateral
prefrontal cortex (DLPFC), hippocampus and amygdala
and such connections have been reported in human ima-
ging studies using diffusion tensor imaging [31]. In our
study, we observed Fc differences for all BG subnuclei
(used as seeds, see methods) between the two groups. In
the case of the putamen and pallidum, increased connec-
tivity in the HF group was observed across some common
structures including the anterior insula, the temporal pole
Figure 4 Functional Connectivity Contrast Maps of the Basal Ganglia Nuclei. Functional connectivity contrast maps of the basal ganglia
nuclei during intermittent heat stimuli (pain threshold +1°C on hand) in high frequency migraine patients vs. low frequency migraine patients.
PCC: Posterior Cingulate Cortex, SM: SupraMarginal, SF: Superior Frontal, ST: Superior Temporal, SP: Superior Parietal, Ins: Insula, Hipp: Hippocampus,
PHipp: Parahippocampus, Fus: Fusiform, Thal: Thalamus, Pulv: Pulvinar, TP: Temporal Pole, MF: Middle Frontal.
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integrative pain processing such as the anterior insula, the
temporal pole and hippocampus. Prior studies from our
group have reported alterations in the temporal pole in
migraine[17]. The increased Fc associated with the ante-
rior insula may reflect complex processing such as intero-
ceptive processing [32] or integration of pain salience into
perceptual decisions [33]. In contrast, decreased connec-
tivity for the caudate was seen for HF < LF migraineurs
with temporal pole, anterior insula in addition to the palli-
dum and middle frontal (MF) cortex. The lower caudate
to pallidum Fc in the HF group may be consistent with
the known intra BG loops and the low Fc parallels the
lower functional activation in the HF group. For the
accumbens, an area that stands out for Fc differences is
the posterior cingulate cortex. This region is implicated in
chronic pain conditions and considered to be important in
consciousness and self-reflection [34].
3.3. Increased Volume in the Caudate Nucleus in HF
Migraineurs
Alterations in function may result in or be produced by
alterations in structure. We propose that during migraine
attacks, sensory inputs to the basal ganglia via direct (noci-
ceptive pathways) or indirect (thalamo-cortical-basal gang-
lia loops) pathways [23], are potentially associated with
structural changes observed here. Significant inputs from
cortical regions including the somatosensory, hippoocam-
pal, orbitofrontal, cindulate and parietal cortex are
well described [20,31]. As such these inputs may act as
drivers to produce significant increase of volume in the
caudate in the HF group. The basis for such changes
remains unknown. However, mechanisms that may explain
increases in caudate volume include: (i) inflammation [35];
(ii) increased iron accumulation [36]; or (iii) increased den-
dritic complexity [37]. Most intriguing however, is the para-
doxical lower response in caudate to noxious heat in the
face of larger volume in the HF group. Increased gray mat-
ter volume in the caudate has been described in other brain
diseases (e.g., Bipolar Disorder [38], and Schizophrenia
[39]), but it should be noted that these increases are oppo-
site to that determined in population studies of caudate
volume in healthy subjects where the volume decreases
with age [40]. The process may be dynamic, since altera-
tions in caudate volume should be considered as a possible
continuum of alterations in the migraine state. It may be a
marker for progression, and future studies will be needed
to verify that.
3.4. Other Considerations
Altered Cortico-Thalamic Inputs May Contribute to Altered
BG function in Migraine
The basal ganglia receive inputs from many brain regions
including the cortex, hippocampus, amygdala and thalamus
[41]. It is also the main recipient of dopamine in the brain
[42]. Migraine produces hyperexcitable cortical [43,44],
and subcortical [45] regions. Given the known connections
with these cortical and subcortical regions (involved in
symptoms of photophobia, phonophobia, osmophobia and
allodynia) and the basal ganglia [20,46] including sensory
information [47], these inputs may contribute to alterations
observed with increased migraine frequency. Exacerbation
of these may be observed as a result of altered chemical
integrity within the BG, for example, cortical stimulation in
dopamine depleted rats results in abnormal function in
basal ganglia circuits [48]. With respect to the latter,
altered dopaminergic function [49] and thus alterations in
reward function may be present in migraine that may be
diminished with increased migraine frequency. The higher
response to heat in the HF group in the nucleus accum-
bens may reflect an alteration in reward systems that have
been reported in other chronic pain conditions [50].
As noted above, migraine is associated with increased
cortical excitability that has been observed in both in chil-
dren and adults [51] presumably as a result of increased
excitatory systems or decreased inhibitory systems. One
potential mechanism of increased caudate volume may
thus relate to this altered state in migraine. Indirect clini-
cal support for this comes from a number of studies: (i) In
ADHD the caudate is smaller, possibly as a result of
diminished inputs or abnormalities of frontal-striatal cir-
cuits [52]. (ii) Caudate volume decreases with age [53,54]
presumably due to increased cortico-basal ganglia inputs
possibly as a result of enhanced cortical inhibitory systems
with age; (iii) Caudate volume loss in diseases where there
is cortical dysfunction or loss as in dementia or diffuse
brain injury [55]. An alternate possibility may relate to the
use of medications (here triptans, amount of usage is
much higher in HF patients) as has been observed in con-
ditions such as schizophrenia (see [56] (See Caveats). Such
alterations may be considered in terms of thalamo-cortico-
basal ganglia circuits (see below) where initial sensory
drive inputs onto diverse cortical circuits (which over time
have increased excitability states) that in turn project back
to the basal ganglia and back to the thalamus [21].
Increased sensitivity in thalamic neurons to pain inputs
from trigemionvascular systems during both ictal and
interictal states may thus drive a sensitized and reverberat-
ing circuit that includes the basal ganglia.
Neuronal Populations and Basal Ganglia Circuitry
We have recently reported direct inputs from trigemino-
vascular neurons in the thalamus to the caudate nucleus
suggesting direct effects of migraine on basal ganglia
function [57]. Differences in responses between low and
high frequency migraineurs may relate to alterations in
excitatory and inhibitory neurotransmitters. Repeated
excitatory inputs acting through glutamatergic receptors
in the BG may provide a basis for increased sensitivity of
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Page 6 of 11activation in the basal ganglia to noxious stimuli. Disinhi-
bitory effects through GABA mediated receptors modu-
late synaptic transmission in the basal ganglia [58,59] and
contribute to this although complex interactions are
likely [59]. Pain may increase excitatory and decreased
inhibitory neurotransmission in other brain regions such
as the amygdala [60]. Given that the majority of striatal
neurons are GABAergic projection neurons, and that
these neurons may modulate striatal output [61], gluta-
matergic activation may induce striatal plasticity includ-
ing long-term depression (LTD) or activation (LTA) [62].
Thus, the functional and morphological changes may
reflect complex alterations due to neurochemical changes
in thalamo-cortical-basal ganglia activity with repeated
migraine attacks (and perhaps in the interictal period)
(see [63]).
Further Support for a Putative Role of BG in migraine
Clinical observations may provide some further insights
on an association supporting a possible role of the basal
ganglia in migraine [64-69,26].
3.5. Caveats
3.5.1. Causal Relationship
The cross-sectional study design we used does not allow
us to distinguish between cause and effect and thus, we
cannot determine with certainty whether the abnormal
brain activity and morphometric changes were causing
the increased number of migraine attacks or solely
caused by them. A longitudinal study would clarify this
issue.
3.5.2. Drug Effects
Aside from migraine frequency, the only other major dif-
ferentiating feature between the two groups was the
higher use of non-steroidal anti-inflammatory drugs
(NSAIDS) and Triptans in the high frequency group.
N S A I D Sa r ec o m m o n l yu s e di nm i g r a i n e[ 7 0 ]a n dm a y
inhibit central sensitization in migraine patients [71] and
may also modulate neuronal activity in the trigeminal
nucleus in animal studies of central sensitization [72].
These drugs are well-known anti-inflammatory agents,
and have a number of effects on brain function (including
analgesia) by acting on neuronal and glial systems. Thus,
t h e s ed r u g sm a ya l s ob eac o n found in this study; how-
ever we are unaware of any study evaluating the effects of
NSAID’s on brain fMRI responses or brain volume.
Direct CNS effects of triptans on the other hand are still
a matter of debate [73], although several lines of evidence
support the presence of direct CNS effects: (i) Triptans,
such as zolmitriptan do cross the blood brain barrier [74]
which may vary according to their lipid solubility; (ii)
Patients display CNS symptoms related to triptans that
can be differentiated from placebo [75]; (iii) 3-H labeled
sumatriptan binding studies of human brain show
increased binding in a number of regions of the brain
including the BG with highest binding in the caudate
[76]; and (iv) There are some reports of triptan-induced
motor changes (dystonia, akathasia) suggestive of actions
of these drugs on the BG [76,77] supporting the post-
mortem binding studies. The only differences between
the groups that we studied were migraine frequency and
concomitant use of triptans (increased in the HF Group).
Thus our observations may be a result of direct triptan-
mediated effects on these structures [78]. Placebo con-
trolled, longitudinal studies are needed to clarify this
issue.
4. Conclusions
A few studies have attempted to evaluate specific basal
ganglia function in pain [14,79,80]. Our findings report
significant alterations in structure and function of the
basal ganglia in migraineuers as a result of repeated
pain, triptan treatment, or both. As such these changes
may reflect alterations that may be indicators of
migraine chronification/transformation.
5. Methods
5.1. Subjects and Study Design
The study met the criteria of the Helsinki accord for
experimentation of pain in human subjects (Helsinki
Accord, 1975; http://history.nih.gov/research/downloads/
helsinki.pdf) and approved informed consent forms were
obtained from all subjects, Figure 5.
Sixty migraine patients were screened for this study out
of which, 20 subjects (n = 10 per group) met the inclusion
criteria, matched for gender, age, and medication type.
The subjects (i) met the criteria for episodic migraine as
classified as per the International Classification for Head-
ache (http://www.ihs-classification.org/en/); (ii) had Beck
Depression Inventory II (BDI-II) scores ≤ 25; (iii) suffered
from episodic migraine for three years or longer; (iv) had
no migraine 72 hours prior to the scan and no symptoms
of developing one during or 24 hours after the scan; and
(v) LF sufferers had 1-2 and HF sufferers had 8-14 head-
ache days per month; and (vi) stable frequency levels were
present for at least a year prior to the scan. None of the
patients reported the use of either opioids of barbiturates
[81]. A detailed history of triptan usage was collected for
each subject.
5.2. Quantitative Sensory Testing
For all functional studies and for all groups, quantitative
sensory testing (QST) was performed using a 1.6 cm ×
1.6 cm contact thermode (TSA-II, Medoc Advanced
Medical Systems, Ramat Yishai, Israel) prior to the MR
session. The temperature increased from a 32°C baseline
temperature at the 1
°C/sec rate until stopped by the sub-
ject at the first onset of pain while the corresponding
temperature was recorded as the pain threshold (THR).
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For stimulation during functional imaging, 3 blocks of
stimulation (30s baseline/15s stimulation @THR+1)
were delivered from a baseline temperature of 32°C
using the same probe that was used during QST. The
rate of temperature change was 4°C/sec. The 15 seconds
pain stimulation period did not include the ramp-up
and ramp-down periods of the thermode from the base-
line temperature. The ramps were modeled in defining
the explanatory variables (EVs) for fMRI data analysis.
5.4. Functional and Structural Imaging
All data were collected on a 3 Tesla Siemens Trio scan-
ner with an 8-channel phased array head coil (Erlangen,
Germany). For structural data, high resolution, T1-
weighted datasets were collected from each patient
using a 3D MPRAGE pulse sequence (TR/TE/TI =
2100/2.74/1100 ms, FA = 12, 128 sagittal slices, res =
1 . 3 3×1 . 0×1 . 0m m
3). For acquiring functional data, a
Gradient Echo (GE) echo planar imaging (EPI) sequence
( T E / T R=3 0 / 2 5 0 0 ,r e s=3 . 5×3 . 5×3 . 5m m
3,m a t r i x=
64 × 64, 74 volumes, 41 slices) was used.
5.5. Data Analysis
5.5.1. Functional Analysis
fMRI analysis was carried out using FMRIB Software
Library (FSL) (http://www.fmrib.ox.ac.uk/fsl), version
4.1.3. The initial two volumes were removed from each
of the functional scans to allow for signal equilibration.
Visual screening of the functional volumes revealed that
none of the subjects showed indications of gross move-
ment (> 1 voxel). The skull and other non-brain areas
were extracted from the anatomical and functional
scans using FSL’s script Brain Extraction Tool (BET).
Motion Correction using FMRIB’s Linear Image Regis-
tration Tool (MCFLIRT) was performed on each func-
tional scan. The volumes were spatially smoothed with a
5 mm full-width at half-maximum filter, and a 60s high-
pass temporal filter was applied. These functional
images were then co-registered with the anatomical
images using FMRIB’s Linear Image Registration Tool
(FLIRT).
First-level fMRI analysis of single subject data was
performed using FMRI Expert Analysis Tool (FEAT)
Version 5.98. The explanatory variables (EVs) for ther-
mal stimuli were entered using the recorded tempera-
ture traces for each subject. Subjects were spatially
normalized to the MNI152 brain for group analysis.
Group activation maps were generated by fMRI expert
analysis tool (FEAT) fMRIB’s Local Analysis of Mixed
Effects (FLAME). For all of the functional comparisons,
the group statistical parametric maps were threshold
using a Gaussian Mixture Model (GMM) technique, a
multiple comparisons-based analysis generally used for
unsupervised classification of data into multiple cate-
gories (Pendse et al., 2007; Moulton et al., 2007). Single
trial averages (STAs) were calculated using in-house
programs.
5.5.2. Structural Analysis
Subcortical volumetric segmentation was performed with
the Freesurfer image analysis software (http://surfer.nmr.
mgh.harvard.edu/). The initial processing steps included
(i) Motion correction and averaging of the two volumetric
T1-weighted MPRAGE images, (ii) Removal of non-brain
tissue using a hybrid watershed/surface deformation
procedure [82], (iii) Automated Talairach transformation,
Figure 5 Subject Recruitment and Experimental Approach. Based on the frequency of migraine attacks per month, Low frequency (LF) and
High frequency (HF) episodic migraine patients were recruited to the study. During the study visit Quantitative Sensory Testing (QST) for pain
threshold was performed for each subject and questionnaires were filled out. For each subject morphological (as part of the anatomical scan)
and functional (evoked to thermal stimuli) images were acquired as shown in the diagram. Thermal stimuli paradigm is also shown in the
diagram.
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Page 8 of 11(iv) Segmentation of the subcortical white matter and deep
gray matter volumetric structures (including hippocampus,
amygdala, caudate, putamen, ventricles) [83,84], (v) Inten-
sity normalization [85]. Subsequent to these processing
steps, the volumes were labeled based on both subject-
independent probabilistic atlas and subject-specific mea-
sured values [83,84]. These labels were then mapped into
Talairach space to achieve point-to-point correspondence
for all subjects. This method uses both intensity and conti-
nuity information from the entire 3-dimensional high
resolution structural volume in segmentation. A univariate
analysis of variance for each of the segmented volumes
was performed separately using IBM SPSS 19.0 statistics
package to assess the differences between the two groups
of migraine patients while accounting for the differences
in the cranium size [86] and age as additional regressors.
5.5.3. Functional Connectivity (Fc) Analysis
Functional connectivity was measured using a seed corre-
lation based approach [87,88]. The evoked functional
connectivity was assessed in order to determine if there
were any differences in the functional connectivity of
each of the seeds of interest to the network they func-
tionally connected to for pain processing between the
two cohorts. Seeds/Regions chosen for functional con-
nectivity analysis were defined anatomically for the basal
ganglia nuclei and also additional subcortical areas (PAG,
Pulvinar and Hypothalamus) based on considerations
that functional connectivity with those areas may reflect
important processing of migraine systems between the
two groups based on our previous studies in migraine
[17]. The basal ganglia ROIs were defined by automatic
segmentation of the T1-weighted anatomical volumes for
each subject individually using Freesurfer image analysis
software (http://surfer.nmr.mgh.harvard.edu/). Other
ROIs were defined on the MNI brain in the standard
space and then transformed to each subject’s anatomical
space.
Preprocessing steps were similar to the steps described
for functional analysis above. For each subject the WM
and CSF masks were created in anatomical space using
Freesurfer tools (http://surfer.nmr.mgh.harvard.edu/). All
time-courses in the brain were orthogonalized with
respect to the eigen time-courses of WM and CSF masks
which were computed by singular value decomposition
(SVD) [89]. fMRI time-courses from each seed ROI were
also extracted using SVD. The time courses were normal-
ized for General Linear Model (GLM) analysis. The
resulting GLM analysis parameter estimates (correlation
coefficients) were transformed into normally distributed
quantities using a Fisher z-transform, registered to MNI
space and entered into a mixed effects group analysis
(FLAME1). The group statistical parametric maps were
threshold using a GMM technique (see above).
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